Selected article for: "human population and low pathogenicity"

Author: Fathi, Anahita; Dahlke, Christine; Addo, Marylyn M.
Title: Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
  • Document date: 2019_9_5
  • ID: 4cia91cq_4
    Snippet: (i) fast production of high titers and its propagation in almost all mammalian cells; (ii) lack of reassortment and corresponding potential to undergo genetic shift in vivo; (iii) inability of the vector's viral RNA to integrate into the host genome; (iv) simple genetic modification with the possibility to accommodate one or multiple antigenic inserts; (v) the low seroprevalence in the human population; (vi) mild pathogenicity in humans; (vii) in.....
    Document: (i) fast production of high titers and its propagation in almost all mammalian cells; (ii) lack of reassortment and corresponding potential to undergo genetic shift in vivo; (iii) inability of the vector's viral RNA to integrate into the host genome; (iv) simple genetic modification with the possibility to accommodate one or multiple antigenic inserts; (v) the low seroprevalence in the human population; (vi) mild pathogenicity in humans; (vii) induction of humoral and cellular immune responses.

    Search related documents:
    Co phrase search for related documents
    • cellular humoral immune response and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cellular humoral immune response and mammalian cell: 1, 2
    • fast production and human population: 1
    • fast production and immune response: 1, 2
    • genetic modification and immune response: 1, 2, 3, 4, 5, 6, 7, 8
    • genetic modification and mammalian cell: 1
    • high titer and human population: 1, 2, 3, 4
    • high titer and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • high titer and low seroprevalence: 1, 2
    • high titer and mammalian cell: 1, 2
    • host genome and human population: 1, 2, 3, 4
    • host genome and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • host genome and mammalian cell: 1, 2, 3, 4
    • human population and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • human population and low seroprevalence: 1, 2, 3, 4, 5, 6
    • human population and mammalian cell: 1, 2, 3, 4, 5, 6
    • human population low seroprevalence and low seroprevalence: 1, 2, 3, 4, 5
    • immune response and low seroprevalence: 1, 2, 3, 4
    • immune response and mammalian cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20